Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471112 | 0.82 | TLR9 (0.37) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL2472571 | 0.80 | ESR2 (0.46) | P2RX7ESR2 | |
| SCHEMBL4492498 | 0.79 | TLR9 (0.47) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL23684873 | 0.77 | ESR2 (0.57) | TLR9TLR7ESR2 | |
| SCHEMBL2469737 | 0.75 | ACHE (0.41) | — | |
| SCHEMBL23683967 | 0.75 | PTGDR2 (0.49) | PTGDR2ESR2 | |
| SCHEMBL2075858 | 0.74 | HTR2C (0.54) | P2RX3TLR9TLR7KITFLT3 | |
| SCHEMBL22204580 | 0.73 | P2RX3 (0.46) | P2RX7P2RX3ESR2 | |
| SCHEMBL29444909 | 0.73 | P2RX3 (0.46) | P2RX7P2RX3ESR2 | |
| SCHEMBL1337705 | 0.73 | PARP1 (0.41) | P2RX7ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370437-B1 | BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-04 | — | — | EP | disclosed |
| US-8309578-B2 | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-11-13 | — | — | US | disclosed |
| US-20110294790-A1 | BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-12-01 | — | — | US | disclosed |
| EP-2370437-A1 | BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS | Nerviano Medical Sciences S.r.l. (IT) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010060854-A1 | BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294790-A1 | BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS | HSP90AB1, HSP90AA1, HSP90AB2P | P2RX7 356/4885PTGDR2 2362/4885P2RX3 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.